Akorn Fights Off Competitive Drugmakers
March 13, 2015 at 22:48 PM EDT
Bottom line: At the end of February 2015, Akorn had 87 ANDAs filed with the FDA, with a combined annual market size of approximately $8.4 billion. This proves that the company can compete with Actavis and Teva, as needed.
